Michigan life sciences insurance. Kalamazoo pharma manufacturing and the Stryker-anchored device corridor.

The Kalamazoo pharma manufacturing cluster centers on Pfizer's sterile injectable manufacturing campus (the largest US sterile injectable facility) plus the long tail of contract manufacturers, packaging operations, and specialty pharma suppliers that grew around the legacy Upjohn footprint. CDMOs serving these operations need cGMP-aligned property programs, products liability sized to large-batch sterile injectable exposures, and recall coverage architected for FDA recalls at commercial scale.

The Grand Rapids and Kalamazoo medical device corridor is anchored by Stryker (headquartered in Kalamazoo with significant Grand Rapids operations) plus a deep bench of orthopedic, surgical, and trauma device manufacturers and contract device manufacturers. Programs in this cluster emphasize products liability towers sized to implantables (often $25M+), MDR liability extensions, GPO supplier compliance for hospital purchase contracts (Vizient, Premier, HealthTrust), and cyber for connected device exposures.

Ann Arbor's Michigan Medicine-anchored cluster supports clinical-stage biotech (Esperion and a long tail of UM-spinouts), clinical research operations, and a smaller medical device footprint. Clinical trial agreements with Michigan Medicine follow patterns familiar to other major academic medical centers, with the institution's contracting office typically active in the redline.

Specialty life-sciences carriers active in Michigan typically coordinate through Chicago or New York underwriters who understand both the pharma manufacturing and the Stryker-anchored device cluster contexts. Premium levels for established manufacturers run roughly comparable to similar operations in Illinois or Pennsylvania; clinical-stage biotech operators in Ann Arbor face the broader specialty market without significant Michigan-specific premium.

The Stryker-adjacent device supplier ecosystem has sufficient operator density that incumbent carriers are familiar with the supplier program coordination question. The Pfizer-Kalamazoo legacy supplier ecosystem typically follows large-pharma supplier program patterns.